Helping the fight against cancer
As opposed to traditional imaging software, our patented DCE-imaging approach enables radiologists to utilize both morphological (RECIST 1.1) as well as functional criteria to evaluate tumor response rate. The latter is done by analysing early perfusion biomarkers.
Our software is capable of predicting treatment effect 4x faster than the state-of-the-art medical software. Consequently, we empower medical experts to select the most adequate cancer treatment in a swift manner and give patients clarity on the road ahead early on.
Hyperfusion's technology integrates with the most common PACS-software and is widely applicable: post-processing analysis of DCE-imaging can be performed on all types of solid tumors.
By applying AI in medical imaging to allow for a swifter and more accurate evaluation of cancer treatment
We're a team of medical experts, artificial intelligence engineers and business people that got together in the beginning of 2019 in a mutual endeavour to make a mark in the fight against cancer.
We believe artificial intelligence and other technological advancements are driving medical science breakthroughs and will reshape the way cancer is diagnosed and treated. As a bio-informatics company, Hyperfusion.ai stands at the vanguard of applying AI to DCE-imaging, with a mission to give patients better and faster feedback on the treatment they are receiving.
By combining a patented methodology with deep learning algorithms and state-of-the-art AI-models, our engineers are denoising DCE-scans and performing non-rigid registrations & automatic segmentation of organs.